Metabolomics Evaluation of the Age-Related Eye Disease Study 2 (AREDS2)
Closed Special Notice Posted
- Solicitation number
- 75N98021P02397
- Agency
-
Office of Logisitics and Acquisition Operations
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Place of performance
- Morrisville, North Carolina 27560, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institutes of Health, on behalf of the National Eye Institute, published a Special Notice to solicit a fixed price contract with Metabolon, Inc. The Notice involves a metabolomics evaluation of approximately 2,001 serum samples from participants aged 55 and older who were enrolled in the Age-Related Eye Disease Study 2 clinical trial to identify metabolites associated with age-related macular degeneration.
The purpose of the Special Notice is to award a contract to Metabolon to perform a non-targeted metabolomics evaluation of the AREDS2 samples. Metabolon will identify over 1,000 metabolites, map them to biological pathways, perform data processing and quality control, and preliminary statistical analysis. The period of performance is 12 months from the date of award. The Special Notice sets an August 23, 2021 deadline for responses and specifies that market research found Metabolon uniquely qualified to complete the metabolomics evaluation within the required timeframe using the available 150 microliter biospecimens. Deliverables include providing final data to NIH and NCATS upon completion.
Notice text
The National Institutes of Health, Office of Logistics and Acquisition Operations (OLAO), Office of Acquisitions (OA), on behalf of the National Eye Institute (NEI) intends to solicit a fixed price contract via FAR 13.5 with Metabolon, Inc., to perform a non-targeted metabolomics evaluation of participants aged 55 and older who were enrolled in the randomized controlled clinical trial Age-Related Eye Disease Study 2 (AREDS2 [2006 to 2012]) with varying severity of age-related macular degeneration (AMD) at baseline and followed longitudinally. Approximately 2,001 samples will be evaluated.
The anticipated period of performance is 12 months from date of award.
NAICS: 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Authority: FAR 13.5. Simplified Procedures for Certain Commercial Items.
This Notice is not a request for proposals, proposal abstracts, or quotations and does not commit the Government to any contractual agreement.
All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency.
Files
| File | Type | Posted |
|---|---|---|
| STATEMENT-OF-WORK-AREDS2 - SAM.pdf | ||
| JOFOC - SAM - Exec.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity